Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cempra's $50M from shrunken IPO leaves development gaps in antibiotic programme

This article was originally published in Scrip

Executive Summary

The US antibiotics developer Cempra Inc, founded in 2006, has successfully gone public, but with a reduced offering. The Chapel Hill, North Carolina-based company raised $50.4 million with expected net proceeds of $46.7 million. But that fell well short of the $70-plus the company was looking for just two weeks ago, meaning that it will still need to raise more cash to complete development of its two lead candidate antibiotics.

Topics

Related Companies

UsernamePublicRestriction

Register

SC016168

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel